BeOne Medicines (BEIGF) Other financing activities (2016 - 2026)

BeOne Medicines (BEIGF) has reported Other financing activities for 11 consecutive years, with $11.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other financing activities fell 66.67% year-over-year to $11.0 million in Q2 2026; TTM through Jun 2026 was $134.7 million, a 10.85% increase from a year earlier, with the FY2025 full-year figure at $196.3 million, up 332.59% from the prior year.
• Other financing activities was $11.0 million for Q2 2026 at BeOne Medicines, down from $23.9 million in the prior quarter.
• Over five years, Other financing activities peaked at $80.5 million in Q3 2025 and troughed at $3.4 million in Q4 2023.
• A 5-year average of $21.1 million and a median of $15.5 million in 2024 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities sank 99.66% in 2022 and soared 495.69% in 2025, its largest moves.
• Over 5 years, Other financing activities stood at $11.3 million in 2022, then tumbled by 70.23% to $3.4 million in 2023, then surged by 161.76% to $8.8 million in 2024, then jumped by 118.79% to $19.2 million in 2025, then sank by 42.59% to $11.0 million in 2026.
• The last three Other financing activities figures came in at $11.0 million (Q2 2026), $23.9 million (Q1 2026), and $19.2 million (Q4 2025), per Business Quant data.